Qyuns is developing a series of antibody drugs targeting autoimmune and allergic diseases. We are willing to collaborate with potential partners who plans to set foot in the field of autoimmune and allergic diseases and have corresponding resources or advantages to develop intended drugs or expand their indication layout, and jointly promote commercialization.

In order to further leverage the value of pipelines and maximize the commercial potential of our products, we plan to authorize the pipeline products in the pipelines as a whole, or by region or indication, to our partners. We believe that relevant strategic cooperation can improve the accessibility of our drugs in the fastest and most cost-effective way.

We are also considering sales collaboration with partners who have strong sales channels for autoimmune or allergic diseases, to jointly promote commercialization in relevant fields and exploit market opportunities as widely as possible.